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IMPORTANCE Collaborative care is an intensive care model involving several health care
professionals working together, typically a physician, a case manager, and amental health
professional. Meta-analyses of aggregate data have shown that collaborative care is
particularly effective in people with depression and comorbid chronic physical conditions.
However, only participant-level analyses can rigorously test whether the treatment effect is
influenced by participant characteristics, such as chronic physical conditions.
OBJECTIVE To assess whether the effectiveness of collaborative care for depression is
moderated by the presence, type, and number of chronic physical conditions.
DATA SOURCES Datawere obtained fromMEDLINE, EMBASE, PubMed, PsycINFO, CINAHL
Complete, and Cochrane Central Register of Controlled Trials, and references from relevant
systematic reviews. The search and collection of eligible studieswas ongoing until May 22, 2015.
STUDY SELECTION This was an update to a previousmeta-analysis. Two independent
reviewers were involved in the study selection process. Randomized clinical trials that
compared the effectiveness of collaborative care with usual care in adults with depression
and reportedmeasured changes in depression severity symptoms at 4 to 6months after
randomization were included in the analysis. Key search terms included depression,
dysthymia, anxiety, panic, phobia, obsession, compulsion, posttraumatic, care management,
case management, collaborative care, enhanced care, andmanaged care.
DATA EXTRACTION AND SYNTHESIS Individual participant data on baseline demographics and
chronic physical conditions as well as baseline and follow-up depression severity symptoms
were requested from authors of the eligible studies. One-stepmeta-analysis of individual
participant data using appropriate mixed-effects models was performed.
MAIN OUTCOMES ANDMEASURES Continuous outcomes of depression severity symptoms
measured using self-reported or observer-ratedmeasures.
RESULTS Data sets from 31 randomized clinical trials including 36 independent comparisons
(N = 10 962 participants) were analyzed. Individual participant data analyses found no
significant interaction effects, indicating that the presence (interaction coefficient, 0.02
[95% CI, −0.10 to 0.13]), numbers (interaction coefficient, 0.01 [95% CI, −0.01 to 0.02]), and
types of chronic physical conditions do not influence the treatment effect.
CONCLUSIONS AND RELEVANCE There is evidence that collaborative care is effective for
people with depression alone and also for people with depression and chronic physical
conditions. Existing guidance that recommends limiting collaborative care to people with
depression and physical comorbidities is not supported by this individual participant data
meta-analysis.
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D epression is the leading global cause of disease bur-den accounting for most disability-adjusted lifeyears.1,2 Thecombinationofdepressionwitha chronic
physical condition(hereinafter termedphysical condition), such
as cardiovascular diseases, respiratory diseases, and diabe-
tes, is associatedwith thegreatestdecrements inqualityof life,
years lost owing to disability,3 patient safety failures, and un-
scheduled care.4-8
A promising intervention for depression in primary care
is collaborative care,9 which involves the use of a case man-
ager (usually nonmedical but also medical; eg, clinical social
workers) working with primary care professionals, often su-
pervised by a mental health specialist and supported by care
management systems. A Cochrane review10 showed that col-
laborative care is more effective than usual care for depres-
sion.
Finding feasible and effectiveways of integrating care for
patientswithdepressionandcomorbidphysical conditions re-
mains a critical goal for health systemsworldwide. There has
been significant interest in the ability of collaborative care to
improve care for people with depression and physical
conditions.11,12 In the United States, the Community Preven-
tiveServicesTaskForce13,14 recommendscollaborative care for
the treatment ofmajor depression in adults but concedes that
there are evidence gaps about the effectiveness of this ap-
proach in people with comorbid physical conditions. In the
United Kingdom, the English organization responsible for
clinical guidelines (National Institute for Health and Care
Excellence)15 recommends that collaborative care should be
considered only for people with depression and comorbid
physical conditionsbasedonresults fromaggregate-datameta-
analyses of 2 sets of trials: collaborative care for patients
with depression and collaborative care for patients with de-
pression andphysical conditions. Although these recommen-
dations were based on the best available evidence at the
time, conducting2 separatemeta-analysesmeans that anydif-
ferences in effectiveness may be confounded by differences
between the trials (eg, location, quality, and intervention for-
mat) and may not be due to physical conditions.16 In addi-
tion, some collaborative care trials that recruited peoplewith
depression would not necessarily have excluded those with
physical conditions, especially trials conducted inolderpopu-
lations in whom such conditions are highly prevalent.17-25
To reach international consensus about the most effec-
tiveways tomanagedepression it is critical that guidelines re-
flect themost robust analysis of themost current data. There
is increasing recognition that individual participantdata (IPD)
meta-analysis is a better basis formodeling treatment effects
than are aggregate data meta-analyses.26 Individual partici-
pantdatameta-analysis ismoreprecisebecause it involves the
applicationof standardizedanalyses acrossmultipledata sets,
overcomes sample size and reporting issues, and allowsmore
sophisticatedmodeling ofmoderator effects.26-28 In this con-
text, IPDallows formoreaccurate codingof comorbiditybased
on actual patient health.
In the present study, we used IPD meta-analysis to test
whetherphysical conditionsmoderate theeffectivenessof col-
laborative care for depression outcomes. First, we examined
whether studies that recruited individualswith physical con-
ditions as part of inclusion criteria demonstrated greater ef-
fect of collaborative care ondepressionoutcomes (ie, a study-
levelmoderatoranalysis). Subsequently,weexaminedwhether
the effectiveness of collaborative care on depression out-
comes was moderated by the presence, number, and type of
physical conditions reportedby individual participantswithin
trials (ie,participant-levelmoderatoranalyses).Theresultswill
provide a rigorousbasis for recommendations about the types
ofpeoplemost likely tobenefit fromcollaborativecareandcon-
tribute to the wider debate about how multimorbidity influ-
ences treatment effectiveness.29,30
Methods
This IPD meta-analysis was conducted and reported accord-
ing topublishedmethodologicalguidelines.31,32ThePRISMA-D
was completed (eTable 1 in the Supplement).
Information Sources
ThepublishedCochranereview10ofcollaborativecarewasused
to identify eligible randomizedclinical trials (RCTs). TheCoch-
rane reviewsearcheswereupdated inMarch2014 (MEDLINE,
EMBASE, PsycINFO, Cochrane Central Register of Controlled
Trials, andCINAHLComplete) but search andcollectionof eli-
gible studieswasongoinguntilMay22, 2015.Key search terms
includeddepression, dysthymia, anxiety, panic, phobia, obses-
sion, compulsion, posttraumatic, caremanagement, caseman-
agement, collaborative care, enhanced care, andmanaged care.
The reference lists of reports of all included studies were
screened for additional studies.Wealso askedauthorsof stud-
ies reviewed to identify additional published studies and trials
in progress.
Eligibility Criteria
Weused the same inclusion criteria reported by theCochrane
review,10 except we excluded studies conducted in adoles-
cents and studies that did not report a depression outcome
(eMethods in the Supplement). The following factors were
evaluated in study selection:
Key Points
Question Is collaborative care more effective for patients with
depression and chronic physical conditions compared with
patients with depression alone?
Findings This meta-analysis of individual participant data from
10960 patients found no significant differences in the treatment
effects of collaborative care between patients with depression
alone and patients with depression and chronic physical
conditions.
Meaning Collaborative care is an equally effective way to deliver
depression care for patient with and without comorbid chronic
physical conditions; existing guidance that recommends limiting
access to collaborative care for patients with depression and
chronic physical conditions should be updated.
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1. Adults (age≥18years)withdepressionormixedanxietyand
depressive disorder,
2. Collaborative care interventions (multiprofessional ap-
proach topatient care, structuredmanagementplan, sched-
uled patient follow-ups, and enhanced interprofessional
communication),
3. Comparison (usual or enhanced usual care),
4. Outcome (continuous depression scores), and
5. Research design (RCTs or cluster RCTs).
Measuring Depression and Physical Conditions
All studies provided continuous depression scores mea-
sured using validated scales, including the Beck Depression
Inventory,33 the Center for Epidemiologic Studies Depres-
sion Scale,34 the Hamilton Rating Scale for Depression,35
and the Patient Health Questionnaire–9.36 We focused on
short-term depression outcomes reported between 4 and 6
months after randomization. Depression scores were stan-
dardized within each study, using the baseline SD and the
follow-up mean score.
At study level, 9 of the 36 comparisons recruited partici-
pants with a physical condition. Thirty of the 36 compari-
sons reported data on the presence and number of physical
conditions at individual participant level. Of these, most
comparisons (21 [58%]) used validated comorbidity indices,
such as the Charlson Comorbidity Index,37 and 6 (17%) used
empirical lists of physical conditions. Seventeen compari-
sons (47%) identified the type of physical conditions among
participants. Based on these data, we were able to create 5
categories of physical conditions: cancer (10 comparisons),
cardiac disease (16 comparisons), diabetes (17 comparisons),
hypertension (11 comparisons), and respiratory disease (11
comparisons).
Data Extraction and Preparation
We contacted the study authors to obtain primary data sets
for the following data: treatment group, age, sex, baseline
and follow-up depression scores, and number and types of
physical conditions (eTable 2 in the Supplement). Received
data were cleaned, converted into the same reporting format,
and aggregated into a single data set. Initial separate analyses
on depression outcomes were conducted for each study to
ensure that our analyses were consistent with those reported
in the original study. We extracted data from the published
reports of all the eligible studies using a standardized Excel
(Microsoft Inc) data extraction form. Data on populations,
interventions, chronic conditions (used as moderator in the
analyses), risk of bias, and outcome effect sizes were also
extracted. Studies with data available to us were compared
with studies with unavailable data in terms of outcome effect
sizes and moderator analyses.
Missing Data
Multiple imputation techniques were used to obtain more
complete data sets and to better protect against bias due to
data missing at random mechanisms. Missing values for
age and depression scores at follow-up were imputed
with a multivariate imputation algorithm (mi impute mvn in
Stata, version 14; StataCorp LP) using Markov chain Monte
Carlo.38,39 This process produces several data sets, each
of which is analyzed separately using the prespecified
model; the results are then combined using Rubin’s rules,40
which account for uncertainty in imputed values. A total
of 1000 new data sets with the observed and imputed
scores for age and depression at follow-up were generated
based on values obtained from study identification number,
treatment group, baseline depression score, and sex. The
range of imputed values was limited to the range of
observed values of the variables. Time series and autocorre-
lation plots of the worst linear function were performed to
monitor the convergence of the generated imputation
algorithms.41,42 We examined whether baseline variables
(study, treatment group, age, sex, and baseline depression
scores) predicted missing data to confirm that the assump-
tions underlying imputations were met. Sensitivity analyses
were performed using only cases with available data; no sig-
nificant differences were detected in any of the reported
results.
Statistical Analysis
One-stepmeta-analysiswasundertakenbecause it is less sus-
ceptible to bias, is most efficient in terms of power, and al-
lows for sophisticated modeling of covariates (age, sex, and
baseline depression scores in the present study).43,44 A 1-step
IPD meta-analysis constructs a model for the hypothesized
treatment-covariate associations across all IPD setswhile sta-
tistically accounting for clustering at the level of each in-
cluded data set.28,45
Appropriate mixed-effects models (fixed study-specific
intercepts, random treatment effect, and fixed study-
specific effects for baseline depression) were used to meta-
analyze the participant-level data and estimate the between-
study and within-study variances and the effects of
covariates.46 Clustered RCTs were statistically accounted for
in the model by adhering to the methodologic recommenda-
tions of Sutton et al.47 The Stata, version 14, commandmixed
was used through the ipdforest command to summarize the
evidence by study and obtain forest plots.48,49 A 1-stage
meta-analysis variant of the I2 statistic was used to assess
heterogeneity.50 We examined the impact of covariates sepa-
rately, building a model based on both statistical and theo-
retical criteria. If studies included multiple treatment groups
and a single control group, the treatment groups were
treated as separate comparisons in the analyses, whereas,
the control groups were halved at random to avoid double
counting in the analyses. In accordance with published
guidelines,51 funnel plots were constructed to assess the
potential for publication bias.
Several prespecified primary analyses were performed.
One analysis examined a study-level moderator (binary vari-
able;participantswithphysical conditionsaspartof thestudy’s
inclusion criteria: yes, 1; no, 0). The other analyses examined
moderatorsatpatient level including thepresence (binaryvari-
able; present, 1; absent, 0), number (continuousvariable), and
types of physical conditions (binary variables for each condi-
tion; present, 1; absent, 0).
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We conducted 2 secondary analyses to examine the
robustness of the results and assessed whether the results
remained the same after controlling for the risk of bias
scores of the studies (based on allocation concealment item).
Allocation concealment was selected as an indicator of risk
of bias because it is the most sensitive item to changes in the
treatment effect, especially when based on self-reported
outcomes.52-54 We also explored whether the main effects
were influenced by the measure used to assess physical con-
ditions (use of validated comorbidity severity indices).
Results
Figure 1 presents the flowchart of the study selection pro-
cess. A total of 76 RCTs (22 284 patients) including 86 inde-
pendent comparisons were eligible for inclusion in the IPD
meta-analysis. We found no evidence of asymmetry in the
funnel plot for these studies (Egger regression test intercept
[SE], −0.54 [0.42]; P = .21) (eFigure 1 in the Supplement). We
collected data from 32 trials (11 531 [51.7%] of the total num-
ber of participants) that included 37 comparisons. One RCT55
(a pilot study based on 49 participants) was excluded from
the analyses because it did not include data on age and sex,
leaving 36 comparisons. A total of 569 individual cases
(4.9%) were excluded from the analyses because of missing
baseline values on depression or age, leaving 10962 unique
cases (of which 1819 [16.6%] were imputed using multiple
imputations).
Baseline Characteristics and Comparisons Between
Available and Unavailable Data
Eighteenstudieswere conducted in theUnitedStates, 11 inEu-
rope, 1 inCanada,and1 in India.Mostparticipantswerewomen
(7749 [70.7%]); mean (SD) age was 51 (15) years (range, 17-97
years). Most participants (8099 [78.1%]) had at least 1 physi-
cal condition with a mean of 2.5 (2.3) conditions. We identi-
fiedno important issueswhile checking the IPD.Details on the
characteristics of the studies are presented in eTable 3 and
eTable 4 in the Supplement.
Figure 1. PRISMA Flowchart
3473 Records after duplicates removed
44 Studies provided data on the outcome
measure (severity of depression
symptoms)
Aggregate data
44 Studies included in analysis
(49 comparisons)
10 753 Participants included in analysis
Individual patient data
31 Studies included in analysis 
(36 comparisons)
10 962 Participants included in analysis
569 Participants excluded (multiple
imputation impossible for
these cases)
3620 Records identified through
database searching
44 Additional records identified
through other sources
10 Studies excluded
2 Adolescents
8 No depression outcome
76 Number of studies for which IPD were
sought (trials with 86 independent
comparisons)
44 Studies for which IPD were not
provided (10 753 participants)
25 Nonresponse
7 Ethical barriers
6 Contact loss
6 Time constraints
32 Studies for which IPD were provided
(37 comparisons)
11 531 Participants for whom data
were provided
86 Eligible studies
79 Studies included in Cochrane
review (including 90 comparisons)
7 Studies identified from search
updates and author requests
Flowchart of the inclusion of studies
in the review. IPD indicates individual
participant data.
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Available andunavailable studieswere compared in terms
of population, intervention, and risk of bias characteristics, as
well as outcome data. We selected these specific characteris-
tics based on the results of 2 previous reviews12,16 that ap-
plied meta-regression analyses to identify moderators of the
main effect of collaborative care interventions. As reported in
the Table, the only statistically significant difference identi-
fied was for the intervention content; a larger proportion of
trials that incorporatedpsychological interventionsmadedata
available.
Effects of Collaborative Care on 3 Depressive Symptoms
at 4- to 6-Month Follow-up
Collaborative carewas associatedwith a small but significant
effectondepressionoutcomescomparedwithusual care (stan-
dardized mean difference [SMD], −0.22 [95% CI, −0.25 to
−0.18]; I2 = 0.8%; 0.3%-3.5%) (eFigure 2 in the Supplement)
equal to adropof approximately2pointson thePatientHealth
Questionnaire–9 above the change in the controls. This effect
size was smaller but not significantly different from the ef-
fect size reported inaCochrane review10 (−0.28 [95%CI, −0.31
to −0.25]; P = .227) (Table).
Association Between Systematic Identification of Patients
with Chronic Physical Conditions and the Effectiveness
of Collaborative Care on Depression Scores
A statistically significant interactionwas found between sys-
tematic identification of participants with physical condi-
tions in the study and treatment effect (interaction coeffi-
cient, −0.12 [95%CI, −0.23 to −0.02]) (Figure 2).12,19,21,24,56-82
Randomizedclinical trials that explicitly recruitedpeoplewith
physical conditions were associated with significantly larger
treatment effects for depression (SMD, −0.29 [95% CI, −0.37
to −0.21]) compared with RCTs that did not explicitly recruit
people with physical conditions (SMD, −0.19 [95% CI, −0.23
to −0.15]). Themoderating effect of inclusionof physical con-
ditionswas even larger in trialswith adequate concealment of
allocation (interaction coefficient, −0.14 [95% CI, −0.26 to
−0.02]).
Association Between Presence of Chronic Physical
Conditions and the Effectiveness of Collaborative Care
on Depression Scores
When we compared the effects of collaborative care in par-
ticipants with and without physical conditions, the interac-
tion termwith the treatment effectwas nonsignificant (inter-
action coefficient, 0.02 [95% CI, −0.10 to 0.13]) (Figure 3)
(References 12, 19, 21, 24, 56, 57, 59, 60, 63, 65-72, 74-82).We
could not demonstrate any statistically significant moderat-
ing effect of the presence of physical conditions on depres-
sionoutcomes at follow-up (effect in thosewithphysical con-
ditions: SMD, −0.21 [95%CI, −0.27 to −0.15], in thosewithout
physical conditions: SMD, −0.23 [95% CI, −0.32 to −0.12])
(Figure 3).
This resultwasnot sensitive toallocationconcealment rat-
ings (adequate: interaction coefficient, −0.06 [95%CI, −0.04
to 0.02]) or to themeasure used to assess physical conditions
(validated: 0.05 [95% CI, −0.08 to 0.10]).
Association Between Number of Chronic Physical
Conditions and the Effectiveness of Collaborative
Care on Depression Scores
The interaction term between number of physical conditions
and treatment effect was nonsignificant (interaction coeffi-
cient, 0.00 [95%CI, −0.01 to 0.02]) (Figure 4) (References 12,
19, 21, 24, 56, 57, 59, 60, 63, 65-72, 74-82). This finding sug-
gests that the improvement of depression scores at follow-up
does not differ according to the number of physical condi-
Table. Comparison of Studies Providing Data for the IPD Analyses and Those Not Providing Data
Variable
Data Unavailable
(n = 49)
Data Available
(n = 36) Statistical Test P Value
Country, United States 36 (78) 23 (62) χ 21,85 = 3.17 .08
Publication date, y
Mean (SD) 2006 (4.03) 2007 (5.29) t83 = 1.01 .32
Median (range) 2007 (1995-2013) 2008 (1995-2015)
Systematic recruitment
method, No. (%)
41 (84) 31 (84) χ 21,85 = 0.01 .98
Chronic physical condition
present, No. (%)
12 (24) 9 (24) χ 21,85 = 0.01 .97
Intervention content
psychological or both,
No. (%)
20 (41) 28 (76) χ 21,85 = 12.79 <.01
Frequency of scheduled
supervision, mean (SD)
1.64 (0.82) 1.76 (0.91) t83 = 0.65 .52
Allocation concealment low
risk, No. (%)
30 (61) 18 (49) χ 21,85 = 3.17 .24
Sample size
Mean (SD) 220 (305) 292 (192) t83 = 1.63 .11
Median (range) 165 (23 to 1570) 227 (64 to 783)
Effect size
SMD (SE) −0.32 (0.31) −0.24 (0.30) t83 = 1.22 .23
SMD (95% CI) (−0.40 to −0.23) (−0.29 to −0.10)
Abbreviations: IPD, individual
participant data; SMD, standardized
mean difference.
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tions. The interaction effect was not significantly affected by
the allocation concealment rating (interaction coefficient,
−0.00 [95% CI, −0.03 to 0.03]) or by the measure used to as-
sess physical conditions (interaction coefficient, −0.01 [95%
CI, −0.04 to 0.02]).
Association Between Types of Chronic Physical
Conditions and the Effectiveness of Collaborative
Care on Depression Scores
We found no evidence that the effects of collaborative care on
depression outcomes are moderated by the types of physical
conditions amongparticipants. Noneof the interaction effects
betweentreatmenteffectandtypesofphysical conditionswere
significant: cancer (interactioncoefficient,−0.11 [95%CI,−0.02
to 0.22]), cardiac disease (interaction coefficient, −0.02 [95%
CI,−0.14 to0.09]),diabetes (interactioncoefficient,−0.02[95%
CI,−0.08to0.09]),hypertension(interactioncoefficient,−0.09
[95%CI,−0.21 to0.03]), andrespiratorydisease (interactionco-
efficient, −0.08 [95% CI, −0.21 to 0.07]). These findings sug-
gest that the benefits derived by collaborative care do not dif-
fer significantly across subgroups of peoplewith certain types
of physical conditions. None of the interaction effects were
Figure 2. Study-Level Analysis Examining the Effect of the Presence Chronic Physical Conditions on the
Effectiveness of Collaborative Care
–0.6–0.9 0.20
Effect Size (95% CI)
–0.3
Weight,
% (ML)
Favors
Collaborative Care
Favors
ControlSource Effect Size (95% CI)
Effect Size (95% CI)
Bruce et al,19 2004 –0.27 (–0.36 to –0.17)
Katon et al,56 1995 –0.31 (–0.57 to –0.05)
Katon et al,57 1996 –0.34 (–0.67 to –0.01)
Katon et al,58 1999 –0.19 (–0.36 to –0.01)
Katon et al,59 2001 –0.15 (–0.28 to –0.02)
Simon  et al,60 2000 –0.17 (–0.29 to –0.04)
Simon et al,60 2000 –0.18 (–0.31 to –0.06)
Simon et al,61 2011 –0.23 (–0.40 to –0.06)
Simon et al,62 2004 –0.32 (–0.45 to –0.20)
Simon et al,62 2004 –0.18 (–0.30 to –0.05)
Melville et al,63 2014 –0.10 (–0.28 to 0.09)
Buszewicz et al,64 2010 –0.21 (–0.31 to –0.11)
Cole et al,24 2006 –0.19 (–0.41 to 0.02)
Ell et al,21 2007 –0.13 (–0.28 to 0.02)
Gensichen et al,65 2009 –0.19 (–0.29 to –0.08)
Menchetti et al,66 2013 –0.15 (–0.31 to 0.02)
Huijbregts et al,67 2013 –0.29 (–0.47 to –0.11)
Vlasveld et al,68 2012 –0.27 (–0.49 to –0.05)
Smit et al,69 2006 –0.22 (–0.39 to –0.05)
Smit et al,69 2006 –0.17 (–0.45 to 0.10)
Smit et al,69 2006 –0.28 (–0.54 to –0.02)
Patel et al,70 2010 –0.18 (–0.29 to –0.07)
Wells et al,71 2000 –0.14 (–0.22 to –0.06)
Wells et al,71 2000  –0.20 (–0.29 to –0.11)
Adler et al,72 2004 –0.13 (–0.25 to –0.02)
Richards et al,73 2009 –0.27 (–0.57 to 0.04)
Richards  et al,74 2013 –0.19 (–0.29 to –0.08)
5.46
0.83
0.58
2.08
3.52
2.69
2.91
1.90
2.70
2.77
1.87
5.02
1.02
2.84
5.67
2.06
1.36
1.13
1.15
0.57
0.61
7.06
5.77
5.06
4.30
0.72
5.30
76.96ML Overall I2 = 0% –0.19 (–0.23 to –0.15)
Studies did not explicitly recruit patients with chronic physical conditionsA
Source
Katon et al,75 2004 –0.22 (–0.42 to –0.03)
Katon et al,76 2010 –0.62 (–0.85 to –0.39)
Davidson et al,77 2013 –0.23 (–0.50 to 0.04)
Ell et al,78 2008 –0.10 (–0.27 to 0.07)
Ell et al,79 2010 –0.41 (–0.60 to –0.22)
Huffman et al,80 2011 –0.26 (–0.53 to 0.01)
Huffman et al,81 2014 –0.29 (–0.60 to 0.02)
Rollman et al,82 2009 –0.20 (–0.41 to 0.01)
Coventry et al,12 2014 –0.29 (–0.46 to –0.13)
Studies explicitly recruited patients with chronic physical conditionsB
–0.6–0.9 0.20
Effect Size (95% CI)
–0.3
Favors
Collaborative Care
Favors
Control
Weight,
% (ML)
2.78
1.95
1.37
4.31
3.53
1.60
1.21
2.76
3.53
23.04ML Overall I2 = 0% –0.29 (–0.37 to –0.21)
Study-level data and pooled effects
across 36 comparisons. A, Studies
that did not explicitly recruit patients
with chronic physical conditions.
B, Studies that explicitly recruited
patients with chronic physical
conditions; mixed-effects model
used. Weights are from
random-effects analysis. ML indicates
maximum likelihood.
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Figure 3. Individual Participant–Level Analysis Examining the Effect of the Presence of Chronic Physical
Conditions on the Effectiveness of Collaborative Care
–1.0 –0.8 –0.6 –0.4 –0.2 0.80.60.40.20
Effect Size (95% CI)
Weight,
% (ML)
Favors
Collaborative Care
Favors
ControlSource Effect Size (95% CI)
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Figure 4. Individual Participant–Level Analysis Examining the Effect of the Number of Chronic Physical
Conditions on the Effectiveness of Collaborative Care
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affected by allocation concealment or by the measure used to
assess physical conditions.
Discussion
Analyzing data from 36 comparisons of collaborative care
and 10 962 participants, this IPD meta-analysis showed
that collaborative care is associated with significant short-
term improvements in depression outcomes across all people
with or without comorbid physical conditions. At study level,
trials that recruited only participants with comorbid physical
conditions were associatedwith larger treatment effects com-
pared with trials that did not include those with comorbid
conditions, confirming previous findings.12,15 However, when
a more accurate analysis at the individual participant level
was undertaken, the presence, number, and type of physical
conditions did not moderate the main effect of collaborative
care on depression outcomes. Overall, the findings of this IPD
meta-analysis do not support existing recommendations
based on meta-analyses of aggregate data that collaborative
care should be considered only for patients with comorbid
depression and physical conditions. Our findings highlight
the importance of undertaking IPD analyses in developing
rigorous recommendations, especially for subgroups of com-
plex patients.
Strengths and Limitations
To our knowledge, this study is the most methodologically
rigorous test of the influence of physical conditions on the
effects of collaborative care on depression outcomes.26,83
However, there are several limitations. Individual participant
data meta-analysis remains vulnerable to important sources
of bias, including publication, study or reviewer selection,
and data availability bias.51 No funnel plot asymmetry was
detected, suggesting that publication bias is not likely to be
present in the overall data set. Study selection bias was mini-
mized by including studies through multiple sources (ie, an
existing standard Cochrane review,10 top-up database
searches, and author requests) using strict prespecification of
trial eligibility criteria. These efforts facilitated access to data
from approximately half of the participants included in pub-
lished RCTs of collaborative care for depression, which is
below the recommended recruitment target (80% of data
requested).51 We observed some differences between avail-
able and unavailable studies, but these differences rarely
reached statistical significance. For example, the overall
effect size was smaller than that found in the previous Coch-
rane review.10 This difference is likely to be explained by the
fact that less than half of all collaborative care trials were
included in this IPD analysis, and these trials were generally
larger than those that were not included. It is important to
continue to develop effective methods and agreements about
data sharing to ensure that future analyses have better access
to data.
Another limitation of the study is that the evaluation of
physical conditions was not pursued in an entirely consis-
tent manner across trials. Most of the trials assessed the
number of physical conditions using validated comorbidity
indexes that contain extensive lists of physical conditions,
but some trials used less-comprehensive lists of physical
conditions that were empirically devised.37 Although we
separately examined the influence of 5 common physical
conditions, participants could have more than 1 of these
conditions. The experience and interactions of multiple
concordant or discordant conditions84 is another possible
factor to recognize why people might respond differently to
depression treatment.
The use of multiple mixed-effects regression analyses of
IPDandcontrolling for covariates significantly reduces thepos-
sibilityofbiaspresent inaggregatedatameta-analyses (eg, eco-
logic fallacy or Simpson paradox).26,83,85-87 However, we rec-
ommend interpreting these findings cautiously since someof
these biases might still operate.
Finally, there were important between-study variations,
including intervention content (collaborative care is gener-
ally heterogeneous)10 and depression measures. However,
these study-level variations are unlikely to influence the
participant-level analyses that showed that chronic physical
conditions do not moderate the effectiveness of collabora-
tive care. A post hoc sensitivity analysis indicated that the
results were similar regardless of using self-reported or
observer-rated measures for depression.
ComparisonWith Previous Systematic Reviews
Previous systematic reviews12,16 have examined moderators
of the effect of collaborative care on depression outcomes
but were based on aggregate data and usedmeta-regressions.
Improved depressive outcomes were predicted by the inclu-
sion of psychological interventions, and the use of antide-
pressant medication was predicted by recruiting people with
physical conditions.12 Based on these findings, it was
proposed12 that patients with physical conditions may derive
greater benefits from collaborative care compared with
patients without physical conditions. As noted above, these
analyses are a less-robust basis for decision making because
they are insensitive to variation in physical conditions at the
level of individual patients. In this IPD meta-analysis, we
found no support for this hypothesis.
Implications for Clinicians, Policymakers, and Researchers
This study suggests that depressed patients with and without
comorbid physical conditions gain important improvements
in depression outcomes from collaborative care. As such, our
findings do not support the recommendation by the National
Institute for Health and Care Excellence that collaborative
care should be considered only for people with depression
and comorbid physical conditions with functional im-
pairment.15 Limiting collaborative care to people with
depression and comorbid physical conditions does not
appear to be a reasonable policy recommendation with
important implications for patient benefit. Individual partici-
pant data meta-analyses are underused in the development
of clinical guidelines, and the next iteration of guidelines for
depression could be improved by using the most-reliable evi-
dence available.88
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Giventhattheeffectivenessofcollaborativecareisconfirmed,
future researchshould focusonunderstandinghowtooptimize
the delivery and outcomes of collaborative care. For instance,
basedonrecentpublishedevidence,89 thesystematicmeasure-
mentandmanagementofphysicalhealthoutcomesalongwith
mentalhealthoutcomeshas thepotential toboost theeffective-
nessofcollaborativecare inpeoplewithphysical comorbidities.
However, theoverall treatmentbenefits associatedwithcollab-
orative care are modest.10 It is therefore legitimate to suggest
that future treatment policy guidelines should also be
grounded on the comparative cost-effectiveness of collabora-
tive care to other types of interventions.
Conclusions
To our knowledge, this IPDmeta-analysis represents themost
rigorous and precise analysis to date on the extent to which
physical conditions influence the effectiveness of collabora-
tive care on depression outcomes. People with depression de-
rivesignificantbenefits fromcollaborativecareregardlessof the
presence,number,or typeofcomorbidphysical conditions.The
core challengenow is tounderstandhowtodeliver these inter-
ventions at scale in routine settings and to better operational-
ize the treatment outcomes tomaximize patient benefits.
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